{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:42:03Z","timestamp":1787805723234,"version":"build-2784847793"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":1152,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":651,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["asbmr.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Inhibition of tissue-nonspecific alkaline phosphatase (TNAP) may prevent ectopic soft tissue calcification by increasing endogenous pyrophosphate (PPi). DS-1211 is a potent and selective novel small molecule TNAP inhibitor with well-characterized pharmacokinetics (PKs) in rodent and monkey. Herein, we report a comprehensive summary of studies establishing the pharmaceutical profile of DS-1211. In vitro studies characterized the mode of inhibition and inhibitory effects of DS-1211 on three human alkaline phosphatase (ALP) isozymes\u2014TNAP, human intestinal ALP, human placental ALP\u2014and on ALP activity across species in mouse, monkey, and human plasma. In vivo PK and pharmacodynamic (PD) effects of a single oral dose of DS-1211 in mice and monkeys were evaluated, including biomarker changes in PPi and pyridoxal 5\u2032-phosphate (PLP). Oral bioavailability (BA) was determined through administration of DS-1211 at a 0.3-mg\/kg dose in monkeys. In vitro experiments demonstrated DS-1211 inhibited ALP activity through an uncompetitive mode of action. DS-1211 exhibited TNAP selectivity and potent inhibition of TNAP across species. In vivo studies in mice and monkeys after single oral administration of DS-1211 showed linear PKs, with dose-dependent inhibition of ALP activity and increases in plasma PPi and PLP. Inhibitory effects of DS-1211 were consistent in both mouse and monkey. Mean absolute oral BA was 73.9%. Overall, in vitro and in vivo studies showed DS-1211 is a potent and selective TNAP inhibitor across species. Further in vivo pharmacology studies in ectopic calcification animal models and clinical investigations of DS-1211 in patient populations are warranted. \u00a9 2022 Daiichi Sankyo, Inc. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).<\/jats:p>","DOI":"10.1002\/jbmr.4680","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T13:48:15Z","timestamp":1661262495000},"page":"2033-2043","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["In Vitro and In Vivo Pharmacological Profiles of DS-1211, a Novel Potent, Selective, and Orally Bioavailable Tissue-Nonspecific Alkaline Phosphatase Inhibitor"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1096-4386","authenticated-orcid":false,"given":"Kaori","family":"Soma","sequence":"first","affiliation":[{"name":"Daiichi Sankyo Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Izumi","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd. Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shojiro","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"issue":"1","key":"2024012714050328200_jbmr4680-bib-0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bmcl.2017.11.024","article-title":"Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor","volume":"28","author":"Pinkerton","year":"2018","journal-title":"Bioorg Med Chem Lett."},{"issue":"4","key":"2024012714050328200_jbmr4680-bib-0002","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00223-015-0079-1","article-title":"Alkaline phosphatase and hypophosphatasia","volume":"98","author":"Mill\u00e1n","year":"2016","journal-title":"Calcif Tissue Int."},{"issue":"7","key":"2024012714050328200_jbmr4680-bib-0003","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nrneph.2017.60","article-title":"Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD","volume":"13","author":"Haarhaus","year":"2017","journal-title":"Nat Rev Nephrol."},{"issue":"14","key":"2024012714050328200_jbmr4680-bib-0004","doi-asserted-by":"crossref","first-page":"9445","DOI":"10.1073\/pnas.142063399","article-title":"Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization","volume":"99","author":"Hessle","year":"2002","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"2024012714050328200_jbmr4680-bib-0005","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1172\/JCI112031","article-title":"Markedly increased circulating pyridoxal-5\u2032-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism","volume":"76","author":"Whyte","year":"1985","journal-title":"J Clin Invest."},{"issue":"4","key":"2024012714050328200_jbmr4680-bib-0006","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1172\/JCI117814","article-title":"Alkaline phosphatase: placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5\u2032-phosphate. Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy","volume":"95","author":"Whyte","year":"1995","journal-title":"J Clin Invest."},{"issue":"2","key":"2024012714050328200_jbmr4680-bib-0007","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jid.2018.07.030","article-title":"Inhibition of tissue-nonspecific alkaline phosphatase attenuates ectopic mineralization in the Abcc6(\u2212\/\u2212) mouse model of PXE but not in the Enpp1 mutant mouse models of GACI","volume":"139","author":"Li","year":"2019","journal-title":"J Invest Dermatol."},{"issue":"4","key":"2024012714050328200_jbmr4680-bib-0008","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0002-9440(10)63208-7","article-title":"Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders","volume":"164","author":"Harmey","year":"2004","journal-title":"Am J Pathol."},{"issue":"21","key":"2024012714050328200_jbmr4680-bib-0009","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/01.CIR.100.21.2168","article-title":"Medial localization of mineralization-regulating proteins in association with M\u00f6nckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification","volume":"100","author":"Shanahan","year":"1999","journal-title":"Circulation."},{"issue":"5","key":"2024012714050328200_jbmr4680-bib-0010","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa0912923","article-title":"NT5E mutations and arterial calcifications","volume":"364","author":"St Hilaire","year":"2011","journal-title":"N Engl J Med."},{"issue":"5","key":"2024012714050328200_jbmr4680-bib-0011","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1172\/JCI106589","article-title":"Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone","volume":"50","author":"Russell","year":"1971","journal-title":"J Clin Invest."},{"key":"2024012714050328200_jbmr4680-bib-0012","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coph.2016.02.002","article-title":"New perspectives on rare connective tissue calcifying diseases","volume":"28","author":"Rashdan","year":"2016","journal-title":"Curr Opin Pharmacol."},{"issue":"2","key":"2024012714050328200_jbmr4680-bib-0013","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1573403X14666181031141226","article-title":"Tissue non-specific alkaline phosphatase and vascular calcification: a potential therapeutic target","volume":"15","author":"Azpiazu","year":"2019","journal-title":"Curr Cardiol Rev."},{"issue":"1","key":"2024012714050328200_jbmr4680-bib-0014","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/cvr\/cvaa299","article-title":"TNAP as a therapeutic target for cardiovascular calcification - a discussion of its pleiotropic functions in the body","volume":"118","author":"Goettsch","year":"2022","journal-title":"Cardiovasc Res."},{"issue":"11","key":"2024012714050328200_jbmr4680-bib-0015","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1359\/JBMR.040608","article-title":"Residues determining the binding specificity of uncompetitive inhibitors to tissue-nonspecific alkaline phosphatase","volume":"19","author":"Kozlenkov","year":"2004","journal-title":"J Bone Miner Res."},{"issue":"11","key":"2024012714050328200_jbmr4680-bib-0016","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.070714","article-title":"Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification","volume":"22","author":"Narisawa","year":"2007","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2024012714050328200_jbmr4680-bib-0017","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/jbmr.2420","article-title":"Pathophysiological role of vascular smooth muscle alkaline phosphatase in medial artery calcification","volume":"30","author":"Sheen","year":"2015","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2024012714050328200_jbmr4680-bib-0018","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/path.5346","article-title":"Inhibition of tissue-nonspecific alkaline phosphatase protects against medial arterial calcification and improves survival probability in the CKD-MBD mouse model","volume":"250","author":"Tani","year":"2020","journal-title":"J Pathol."},{"issue":"393","key":"2024012714050328200_jbmr4680-bib-0019","doi-asserted-by":"crossref","first-page":"eaal1669","DOI":"10.1126\/scitranslmed.aal1669","article-title":"Ectopic calcification in pseudoxanthoma elasticum responds to inhibition of tissue-nonspecific alkaline phosphatase","volume":"9","author":"Ziegler","year":"2017","journal-title":"Sci Transl Med."},{"issue":"4","key":"2024012714050328200_jbmr4680-bib-0020","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/cts.13214","article-title":"Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS-1211, a tissue-nonspecific alkaline phosphatase inhibitor","volume":"15","author":"Maruyama","year":"2022","journal-title":"Clin Transl Sci."},{"key":"2024012714050328200_jbmr4680-bib-0021","author":"Miyazaki","year":"2017"},{"issue":"16","key":"2024012714050328200_jbmr4680-bib-0022","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/bph.15178","article-title":"ARRIVE 2.0 and the British Journal of Pharmacology: updated guidance for 2020","volume":"177","author":"Lilley","year":"2020","journal-title":"Br J Pharmacol."},{"issue":"2","key":"2024012714050328200_jbmr4680-bib-0023","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bone.2012.12.048","article-title":"Isozyme profile and tissue-origin of alkaline phosphatases in mouse serum","volume":"53","author":"Linder","year":"2013","journal-title":"Bone."},{"issue":"2","key":"2024012714050328200_jbmr4680-bib-0024","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/0091270012440282","article-title":"Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance","volume":"53","author":"Lombardo","year":"2013","journal-title":"J Clin Pharmacol."},{"issue":"21","key":"2024012714050328200_jbmr4680-bib-0025","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1021\/jm900383s","article-title":"Discovery and validation of a series of aryl sulfonamides as selective inhibitors of tissue-nonspecific alkaline phosphatase (TNAP)","volume":"52","author":"Dahl","year":"2009","journal-title":"J Med Chem."},{"issue":"7","key":"2024012714050328200_jbmr4680-bib-0026","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/1087057109338517","article-title":"Identification and characterization of novel tissue-nonspecific alkaline phosphatase inhibitors with diverse modes of action","volume":"14","author":"Sergienko","year":"2009","journal-title":"J Biomol Screen."},{"issue":"10","key":"2024012714050328200_jbmr4680-bib-0027","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2017.12.062","article-title":"Etidronate for prevention of ectopic mineralization in patients with pseudoxanthoma Elasticum","volume":"71","author":"Kranenburg","year":"2018","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"2024012714050328200_jbmr4680-bib-0028","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1210\/jcem.83.4.4742","article-title":"Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos study group","volume":"83","author":"Roux","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2024012714050328200_jbmr4680-bib-0029","first-page":"269","article-title":"Factors affecting therapeutic compliance: a review from the patient's perspective","volume":"4","author":"Jin","year":"2008","journal-title":"Ther Clin Risk Manag."},{"issue":"7","key":"2024012714050328200_jbmr4680-bib-0030","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/jbmr.2178","article-title":"Clinical and radiographic findings in adults with persistent hypophosphatasemia","volume":"29","author":"McKiernan","year":"2014","journal-title":"J Bone Miner Res."},{"issue":"6","key":"2024012714050328200_jbmr4680-bib-0031","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ajpath.2017.02.009","article-title":"Pyrophosphate supplementation prevents chronic and acute calcification in ABCC6-deficient mice","volume":"187","author":"Pomozi","year":"2017","journal-title":"Am J Pathol."},{"issue":"11","key":"2024012714050328200_jbmr4680-bib-0032","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.15252\/emmm.201707532","article-title":"Oral administration of pyrophosphate inhibits connective tissue calcification","volume":"9","author":"Dedinszki","year":"2017","journal-title":"EMBO Mol Med."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbmr.4680","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbmr.4680","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/37\/10\/2033\/55454203\/jbmr4680.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/37\/10\/2033\/55454203\/jbmr4680.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:45:58Z","timestamp":1710341158000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/37\/10\/2033-2043\/7512343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,8,23]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.4680","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2022-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}